Anacor’s lead asset, crisaborole, is a non-steroidal topical PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. The compound is currently under review by FDA and has a PDUFA date of January 7th 2017. The proposed acquisition of Anacor by Pfizer will help Pfizer to access innovative assets in the dermatology space.
As per prediction, Pfizer can expect 2 bn per month sale.
Sales Expected x 4.5 Times = 9 Bn
So, 5.2 Billion is safe, riskfree and good deal for Pfizer for Anacor.
KERYDIN® (tavaborole) is topical solution 5%—a treatment that attacks toenail fungus at the site of infection.
Kerydin of Anacor is approved by USFDA in july 2014.